March 2, 2016
DxTerity announces new Direct-to-Patient (D2P) platform transforming how researchers run genomic studies
Comprehensive solution makes accessing the right patients anywhere, anytime fast and affordable
DxTerity today announced the launch of its Direct-to-Patient (D2P) platform for population scale genomic studies. With the launch of the D2P platform, DxTerity provides much needed innovation in genomic research by providing unprecedented access to patient samples.
“Obtaining patient samples is often the biggest hurdle to validating and commercializing a new genomic test. Traditional, ‘physician-centric’ studies are expensive and slow, often taking years to complete and costs in the millions of dollars,” said Dr. Bob Terbrueggen, President and CEO, DxTerity. “DxTerity’s D2P platform uses a single centralized institutional review board (IRB), nationwide digital recruitment of patient cohorts, and ‘From Home’ sampling of patients to dramatically lower the burden of clinical studies for both the test developer and the patient. With our D2P service, the patient is the site and sampling and monitoring can be performed anytime, anywhere, and on anyone.”
New era of Direct-to-Patient access
DxTerity’s D2P platform is enabled by a cost-effective, self-administered finger-stick blood collection and nucleic acid stabilization device that can be distributed and returned via standard mail. No refrigeration is required. The device stabilizes both the RNA and DNA in the blood sample enabling full genome and full transcriptome profiling. Once returned to DxTerity, the sample is analyzed in its CLIA-licensed, CAP-certified genomics laboratory.
Included in the D2P platform is electronic consent (e-Consent), electronic data capture (EDC), and electronic patient-reported outcomes (ePROs). Taken together, the D2P platform is capable of executing genomic studies with unprecedented speed, scale, and cost savings that provides more data points than ever before.
“Using our approach, there’s no need for a phlebotomist or physician office visit and no special sample handling is required. This streamlined, integrated approach also makes large-scale longitudinal studies economically feasible. By driving down the cost for accessing participants, and collecting samples more frequently from larger cohorts, DxTerity is providing the ability to gain a much higher resolution picture of disease activity,” added Terbrueggen.
“Another key benefit is the accelerated timeline for starting and completing genomic studies,” Terbrueggen added. DxTerity’s D2P services platform lets organizations enroll patients and begin a study in months, compared to the one or two years it sometimes takes just to recruit and negotiate with the multiple healthcare facilities needed to conduct a large-scale study. Add in the benefits of expanded geographical reach and no patient trips to a blood collection center, and genomic studies can be completed in record time.